David J McConkey
Overview
Explore the profile of David J McConkey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
190
Citations
11756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson 3rd B, Parimi V, Kamanda S, Corney D, Choi W, Hoffman-Censits J, et al.
J Pathol Clin Res
. 2025 Feb;
11(2):e70021.
PMID: 39971624
Sarcomatoid urothelial carcinoma (SUC) is a rare histologic subtype with poor prognosis. While there is known intra-tumoral heterogeneity between individual SUC tumors, the relationship between sarcomatoid and conventional urothelial carcinoma...
2.
Mokkapati S, Manyam G, Steinmetz A, Tholomier C, Martini A, Choi W, et al.
Transl Oncol
. 2025 Jan;
52:102269.
PMID: 39808845
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on...
3.
Mishra A, Sharma A, Gupta K, Banka D, Johnson B, Hoffman-Censits J, et al.
bioRxiv
. 2025 Jan;
PMID: 39763905
The optimization of dosing strategies is critical for maximizing efficacy and minimizing toxicity in drug development, particularly for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study...
4.
McConkey D, Barb J, Smith A, Sears C
Eur Urol Focus
. 2024 Dec;
10(6):877-878.
PMID: 39648093
Recent preclinical and clinical research has established that the microbiome affects response to immunotherapy, and other work has shown that our diet has strong and rapid effects on the microbiome....
5.
Sadhukhan P, Feng M, Illingworth E, Illingworth E, Sloma I, Ooki A, et al.
J Clin Invest
. 2024 Dec;
135(2.
PMID: 39630608
The Hippo signaling pathway plays a key role in tumorigenesis in different cancer types. We investigated the role of the Hippo effector YAP1 in the tumor immune microenvironment (TIME) of...
6.
Steinmetz A, Pierce M, Martini A, Tholomier C, Manyam G, Chen Y, et al.
Front Immunol
. 2024 Nov;
15:1387229.
PMID: 39559365
Introduction: Nadofaragene firadenovec (Ad-IFNα/Syn3) is now approved for BCG-unresponsive bladder cancer (BLCA). IFNα is a pleiotropic cytokine that causes direct tumor cell killing via TRAIL-mediated apoptosis, angiogenesis inhibition, and activation...
7.
Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400287.
PMID: 39499893
Purpose: Alterations in DNA damage response (DDR) genes, including , have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314...
8.
Narayan V, Tholomier C, Mokkapati S, Martini A, Caruso V, Goudarzi M, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39406613
Background And Objective: Urinary tumor DNA (utDNA) profiling identifies mutations associated with urothelial carcinoma and can be used to detect minimal residual disease (MRD). We evaluate the utility of utDNA...
9.
Johnson Iii B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, et al.
Bladder Cancer
. 2024 Aug;
10(2):133-143.
PMID: 39131872
Background: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. Objective: We evaluated the clinical activity and safety of...
10.
Plumber S, Tate T, Al-Ahmadie H, Chen X, Choi W, Basar M, et al.
Nat Commun
. 2024 Aug;
15(1):6538.
PMID: 39095358
Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the...